



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/526,695	03/08/2006	Bjorn Frendus	12578/46501	7946
26646	7590	06/26/2008	EXAMINER	
KENYON & KENYON LLP ONE BROADWAY NEW YORK, NY 10004			STEELE, AMBER D	
ART UNIT	PAPER NUMBER			
			1639	
MAIL DATE	DELIVERY MODE			
			06/26/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/526,695	<b>Applicant(s)</b> FRENDEUS, BJORN
	<b>Examiner</b> Amber D. Steele	<b>Art Unit</b> 1639

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(o).

#### Status

- 1) Responsive to communication(s) filed on \_\_\_\_\_.
- 2a) This action is FINAL.      2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) \_\_\_\_\_. is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_. is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_. is/are allowed.
- 6) Claim(s) \_\_\_\_\_. is/are rejected.
- 7) Claim(s) \_\_\_\_\_. is/are objected to.
- 8) Claim(s) 31-59 are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_. is/are: a) accepted or b) objected to by the Examiner.  
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All    b) Some \* c) None of:
  1. Certified copies of the priority documents have been received.
  2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement (PTO/SB/08) \_\_\_\_\_  
 Paper No(s)/Mail Date \_\_\_\_\_
- 4) Interview Summary (PTO-413)  
 Paper No(s)/Mail Date \_\_\_\_\_
- 5) Notice of Informal Patent Application
- 6) Other: \_\_\_\_\_

**DETAILED ACTION**

***Status of the Claims***

1. Claims 1-30 were originally filed on March 3, 2005.

The preliminary amendment to the claims received on March 3, 2005 canceled claims 1-30 and added new claims 31-59.

Claims 31-59 are currently pending and under consideration.

***Election/Restrictions***

2. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 31, 34-38, and 40-54, drawn to a method of isolating at least one anti-ligand via utilizing a library (i.e. wet bench method) and the equation of claim 38.

Group II, claim(s) 31, 34-37 and 39-54, drawn to a method of isolating at least one anti-ligand via utilizing a library (i.e. wet bench method) and the equation of claim 39.

Group III, claim(s) 32-38 and 40-54, drawn to a method of isolating at least one anti-ligand via utilizing data set(s) (i.e. in silico; bioinformatics method) and the equation of claim 38.

Group IV, claim(s) 32-37 and 39-54, drawn to a method of isolating at least one anti-ligand via utilizing data set(s) (i.e. in silico; bioinformatics method) and the equation of claim 39.

Group V, claim(s) 55, drawn to a method for preparing a pharmaceutical composition.

Group VI, claim(s) 56, drawn to a pharmaceutical composition.

Group VII, claim(s) 57, drawn to a method for preventing, treating, imaging, or diagnosing a disease.

Group VIII, claim(s) 58-59, drawn to a computer readable medium comprising program code.

3. The inventions listed as Groups I-VIII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the common technical feature is an anti-ligand (Groups I-VII) and a computer program (Groups III-IV and VIII) which are known in the prior art.

Specifically, Venton et al. (U.S. Patent 5,366,862 issued November 22, 1994) teach an anti-ligand which can be utilized as a pharmaceutical composition, methods of screening, methods of preparing, etc. (please refer to the entire specification particularly the Detailed Description section).

Furthermore, Weitz et al. (U.S. Patent 5,688,507 issued November 18, 1997) teach a computer program utilized to model anti-ligand binding, etc. (please refer to the entire specification particularly the Detailed Description section).

Therefore, the common technical features of an anti-ligand and a computer program are known in the prior art and are not considered special.

4. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

A. A species of separation/isolation means (see claims 40-49). Applicants must also elect a species of density (see claims 43-44 and 47).

5. Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Art Unit: 1639

6. Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

7. The claims are deemed to correspond to the species listed above in the following manner:  
For Groups I-IV, claims 40-49.

8. The following claim(s) are generic: For Groups I and II, claim 31 is generic and for Groups III-IV, claim 32 is generic.

9. The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: the various separation and isolation means require different reagents and different structures.

10. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

11. The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

***Future Communications***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amber D. Steele whose telephone number is 571-272-5538. The examiner can normally be reached on Monday through Friday 9:00AM-5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James (Doug) Schultz can be reached on 571-272-0763. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Amber D. Steele/  
Patent Examiner, Art Unit 1639

June 23, 2008